Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World October 1, 2014 Phillip Broadwith	J&J to buy antiviral specialist Alios Johnson and Johnson has agreed to buy antiviral specialist Alios BioPharma for $1.75 billion
Chemistry World December 3, 2013 Phillip Broadwith	New wave of hepatitis C drugs hits US shore Johnson & Johnson's hepatitis C drug Olysio (simeprevir) has been approved by the US Food and Drug Administration.
The Motley Fool November 18, 2011 Brian Orelli	This Biotech Stock Rose for All the Wrong Reasons Achillion Pharmaceuticals announces it might get bought and shares jump by as much as 17% today in response to the report, although it's pulled back a little since then.
Chemistry World June 12, 2014 Philli Broadwith	Merck & Co bolsters hepatitis C pipeline with Idenix acquisition US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion.
Chemistry World August 22, 2013 Phillip Broadwith	J&J buys Aragon's prostate cancer arm Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
The Motley Fool July 27, 2011 Brian Orelli	Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication.
The Motley Fool March 27, 2007	Fast Pitch: Vertex Pharmaceuticals 2007 is expected to be a very eventful year for the pharmaceutical, as it will furnish some important clinical trial results for its investigational drugs. Investors, take note.
Fast Company March 2015 J.J. McCorvey	How Drug Company Gilead Outpaces Its Competitors -- And Common Diseases Over the past few years, Gilead has ushered through four effective new treatments for HIV alone.
The Motley Fool June 30, 2006 Stephen D. Simpson	Johnson & Johnson: This Is More Like It Filling out the drug and device businesses will be good for growth. Investors, take note.
Chemistry World October 30, 2013 Phillip Broadwith	Vertex to cut 370 jobs US biopharmaceutical firm Vertex is cutting 370 jobs as it faces a drop in demand for its hepatitis C drug Incivek (telaprevir).
The Motley Fool October 31, 2011 Brian Orelli	Gunning for the Leaders Hepatitis C drugs take center stage.
Pharmaceutical Executive June 1, 2014 Jill Wechsler	What Price Innovation? Payers, drug plans seek clear assessment of drug value to rationalize high drug prices.
Chemistry World September 23, 2014 Phillip Broadwith	Gilead licenses generic hepatitis C drug in India Gilead has granted licenses to seven generic drugmakers to produce its blockbuster hepatitis C drug Sovaldi (sofosbuvir) in India and 90 other developing nations.
Chemistry World March 26, 2014 Phillip Broadwith	$1.2bn J&J deceptive marketing fine overturned The Arkansas Supreme Court has overturned a lower court's fine of $1.2 billion, imposed on Johnson & Johnson's subsidiary Janssen in April 2012 over its marketing of antipsychotic drug Risperdal (risperidone).
The Motley Fool April 26, 2011 Brian Orelli	There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost.
The Motley Fool October 19, 2007 Brian Lawler	Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down.
The Motley Fool March 20, 2008 Brian Lawler	Gilead Not Slowing Gilead Sciences gets a new approval for a drug.
The Motley Fool November 30, 2011 Brian Orelli	Up Big With Room to Run Lofty hep C valuations are par for the course.
The Motley Fool July 7, 2011 Brian Orelli	J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo.
BusinessWeek October 10, 2005	J&J: How A Dealmaker Nurtures Newcomers Johnson & Johnson has a good track record for retaining employees after a takeover. The company's broadly decentralized structure, which gives managers great leeway - no small thing for execs used to running their own shows.
The Motley Fool November 21, 2011 David Williamson	Pharmasset Acquired, Shares Jump 85% Gilead Sciences buys Pharmasset and hepatitis C drug PSI-7977.
The Motley Fool October 7, 2011 Brian Orelli	A Little Help, Please Gilead pumps up the pipeline.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
The Motley Fool January 9, 2012 Brian Orelli	3 Reasons Hep C Premiums Might Not Last Careful what you wish for.
Pharmaceutical Executive November 1, 2014 Jill Wechsler	Outrage Grows Over Drug Pricing Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge.
The Motley Fool November 26, 2007 Brian Orelli	Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly.
Chemistry World February 19, 2015 Andrew Turley	Hepatitis C drug patent challenged in Europe A French healthcare campaign group has launched a legal challenge to the patent covering Sovaldi (sofosbuvir), the blockbuster hepatitis C virus drug marketed by Gilead.
The Motley Fool October 14, 2008 Brian Orelli	Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace.
The Motley Fool June 14, 2011 Brian Orelli	Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma.
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?
BusinessWeek January 30, 2006 Robert Barker	Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber.
Pharmaceutical Executive November 1, 2014 Casey McDonald	Advocacy Beat: Progress in Global Access to TB Drugs Treatment Action Group reaches a milestone in improving access to much-needed treatments for tuberculosis.
The Motley Fool October 20, 2010 Brian Orelli	What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back.
BusinessWeek September 30, 2009 Arlene Weintraub	J&J Tries to Buy Itself a Pipeline It's snapping up biotechs, spearheading innovative alliances, and reshuffling R&D.
Chemistry World January 6, 2015 Sarah Houlton	Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion.
The Motley Fool February 27, 2007 Brian Lawler	Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors.
The Motley Fool July 28, 2011 Melly Alazraki	J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet.
The Motley Fool January 24, 2006 Stephen D. Simpson	Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did.
Chemistry World December 9, 2009 Sarah Houlton	New hep C breakthrough A drug being developed by Denmark's Santaris Pharma could provide a breakthrough in the treatment of hepatitis C, and positive results in a study on chimpanzees point to its potential to avoid drug resistance.
The Motley Fool July 27, 2011 Alexander Crawford	Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve?
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock.
The Motley Fool September 25, 2009 Brian Orelli	Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK.
The Motley Fool May 20, 2011 Andrea Kalvesmaki	Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.
The Motley Fool September 27, 2005 Jack Uldrich	A Ray of Hope for Flamel? New hepatitis C treatment offers a ray of hope to the ailing nanotech company. Unfortunately, this news does not guarantee sunnier days ahead.
The Motley Fool November 22, 2006 Brian Lawler	Dueling Fools: Johnson & Johnson Bear Rebuttal The bottom line is that investors are putting their faith in the ability of J&J's management to acquire its way to renewing top-line growth in the coming years.
The Motley Fool December 31, 2007 Brian Orelli	Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008.
Chemistry World February 4, 2014 Andy Extance	J&J puts trial data in independent hands In a first-of-its-kind deal, Pharmaceutical firm Johnson & Johnson is making all of its drug trial data available via Yale University, US.
Salon.com August 22, 2000 David Tuller	Battling the pharmaceutical Microsoft Hepatitis C activists are angry about Schering-Plough's decision to "bundle" two drugs, one of which is a potentially life-saving pill not available anywhere else.
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull There are many ways to expose one's portfolio to the health-care industry. But J&J offers the best upside potential at relatively little risk.